NO20066054L - behandling med cisplatin og en EGFR-inhibitor - Google Patents

behandling med cisplatin og en EGFR-inhibitor

Info

Publication number
NO20066054L
NO20066054L NO20066054A NO20066054A NO20066054L NO 20066054 L NO20066054 L NO 20066054L NO 20066054 A NO20066054 A NO 20066054A NO 20066054 A NO20066054 A NO 20066054A NO 20066054 L NO20066054 L NO 20066054L
Authority
NO
Norway
Prior art keywords
cisplatin
kinase inhibitor
treatment
egfr kinase
egfr inhibitor
Prior art date
Application number
NO20066054A
Other languages
English (en)
Inventor
Brian Higgins
Kenneth Kolinsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20066054L publication Critical patent/NO20066054L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for fremstilling av et medikament for behandling av tumorer eller tumormetastaser, kjennetegnet ved at det anvendes en terapeutisk effektiv mengde av en EGFR-kinaseinhibitor og cisplatin, med eller uten ytterligere midler eller behandlinger, så som andre antikreftmedikamenter eller strålingsterapi. Oppfinnelsen omfatter også et farmasøytisk preparat som består av en EGFR-kinaseinhibitor- og cisplatinkombinasjon i kombinasjon med en farmasøytisk akseptabel bærer. Et foretrukket eksempel på en EGFR-kinaseinhibitor som kan anvendes ved utøvelse av denne oppfinnelse, er forbindelsen erlotinib-HCl (også kjent som TarcevaTM).
NO20066054A 2004-06-03 2006-12-28 behandling med cisplatin og en EGFR-inhibitor NO20066054L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57679004P 2004-06-03 2004-06-03
PCT/EP2005/005737 WO2005117916A1 (en) 2004-06-03 2005-05-27 Treatment with cisplatin and an egfr-inhibitor

Publications (1)

Publication Number Publication Date
NO20066054L true NO20066054L (no) 2007-01-25

Family

ID=34969379

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066054A NO20066054L (no) 2004-06-03 2006-12-28 behandling med cisplatin og en EGFR-inhibitor

Country Status (14)

Country Link
US (1) US7951405B2 (no)
EP (1) EP1758601A1 (no)
JP (1) JP2008501654A (no)
CN (1) CN1968706A (no)
AU (1) AU2005249206A1 (no)
BR (1) BRPI0510657A (no)
CA (1) CA2567852A1 (no)
IL (1) IL179533A0 (no)
MX (1) MXPA06014002A (no)
NO (1) NO20066054L (no)
NZ (1) NZ551431A (no)
RU (1) RU2006146612A (no)
WO (1) WO2005117916A1 (no)
ZA (1) ZA200610053B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
HRP20090495T1 (hr) * 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
BRPI0511800A (pt) * 2004-06-03 2008-01-15 Hoffmann La Roche tratamento com irinotecano (cpt-11) e um inibidor de egfr
CA2633593A1 (en) * 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20080299113A1 (en) * 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2011106084A1 (en) * 2010-02-24 2011-09-01 Biodesix, Inc. Cancer patient selection for administration of therapeutic agents using mass spectral analysis
WO2013114339A1 (en) 2012-02-02 2013-08-08 The Universityof British Columbia Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
US8718996B2 (en) * 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US9447103B2 (en) 2012-07-27 2016-09-20 Indiana University Research & Technology Corporation Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity
RU2559130C1 (ru) * 2014-04-25 2015-08-10 Федеральное государственное бюджетное учреждение "Медицинский радиологический научный центр" Министерства здравоохранения Российской Федерации (ФГБУ МРНЦ Минздрава России) Способ лечения неоперабельного немелкоклеточного рака легкого
WO2016089873A1 (en) * 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
CN112661739A (zh) * 2020-12-30 2021-04-16 福建省中科生物股份有限公司 一种萜酚类化合物及其与顺铂联用在抗肿瘤医药上的用途
WO2022232024A1 (en) * 2021-04-26 2022-11-03 Crititech, Inc. Cisplatin particles and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DK1202746T3 (da) 1999-08-12 2007-01-02 Wyeth Corp NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
AU2002236572A1 (en) 2000-11-03 2002-05-21 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
WO2002045653A2 (en) 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
KR20030068205A (ko) 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
AU2002315306B2 (en) 2001-05-08 2007-05-17 Merck Patent Gmbh Combination therapy using anti-EGFR antibodies and anti-hormonal agents
BR0309226A (pt) 2002-04-16 2005-02-09 Astrazeneca Ab Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
AU2004266572A1 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Also Published As

Publication number Publication date
AU2005249206A1 (en) 2005-12-15
EP1758601A1 (en) 2007-03-07
CA2567852A1 (en) 2005-12-15
BRPI0510657A (pt) 2007-12-04
MXPA06014002A (es) 2007-02-08
NZ551431A (en) 2010-04-30
ZA200610053B (en) 2008-02-27
CN1968706A (zh) 2007-05-23
RU2006146612A (ru) 2008-07-20
WO2005117916A1 (en) 2005-12-15
IL179533A0 (en) 2007-05-15
US20050271747A1 (en) 2005-12-08
US7951405B2 (en) 2011-05-31
JP2008501654A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
EA202190630A1 (ru) Способы комбинированной терапии
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
WO2006110175A3 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
ZA201907225B (en) Treatment of her2 positive cancers
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
WO2020132560A3 (en) Compositions and methods for cancer therapy
MX2025008524A (es) Métodos y composiciones para la terapia combinada

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application